Biotech Funding Steady: Investors Eye Late-Stage Assets
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
- Latest
- Trending
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
Co-founder Bryant Riley offers $7 per share for B. Riley, valuing it at $212M, amid a significant stock drop this ...
Clover Health reports its first-ever positive net income in Q2 2024, driven by financial growth and a technology-driven care platform.
Nvidia's VP of Finance, Simona Jankowski, departs for a startup role, marking a notable shift amid Nvidia's monumental growth and ...
Shares of Ibotta closed up 17% at $103.25, but dropped slightly to $97.38 today. Tech IPO market may not be ...
Discover why Microsoft has become the world's most valuable public company, with bullish analysts predicting even greater gains and the ...
Amer Sports, the global sports brand known for its craftsmanship and innovation, has filed for a proposed IPO. The company ...
Investors hail Minnesota's "Fantastic Four" local stocks, Hawkins Inc., APi Group, Winmark Corp., and CVRx, for outperforming in 2023.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.